PriceTargets.com logo

Agiliti - AGTI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.88
  • Forecasted Upside: 30.63%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$15.98 As of 03/22/2023 04:24 PM ET
▲ +0.32 (2.04%)

This chart shows the closing price for AGTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agiliti Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGTI

Analyst Price Target is $20.88
▲ +30.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Agiliti in the last 3 months. The average price target is $20.88, with a high forecast of $28.00 and a low forecast of $18.00. The average price target represents a 30.63% upside from the last price of $15.98.

This chart shows the closing price for AGTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Agiliti.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2023CitigroupLower TargetBuy$21.00 ➝ $20.00Low
1/6/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$18.00Low
12/16/2022Bank of AmericaDowngradeBuy ➝ Neutral$19.00Low
11/16/2022UBS GroupLower Target$19.00N/A
11/15/2022Raymond JamesLower TargetOutperform$22.00 ➝ $20.00Low
11/14/2022The Goldman Sachs GroupLower TargetBuy$23.00 ➝ $20.00Low
11/13/2022CitigroupLower TargetBuy$24.00 ➝ $21.00Low
11/11/2022KeyCorpLower TargetOverweight$25.00 ➝ $23.00Low
10/11/2022Morgan StanleyLower TargetOverweight$23.00 ➝ $20.00Low
8/15/2022Raymond JamesLower TargetOutperform$25.00 ➝ $22.00Low
8/11/2022Morgan StanleyLower TargetOverweight$25.00 ➝ $23.00Low
8/10/2022KeyCorpLower TargetOverweight$27.00 ➝ $25.00Low
7/15/2022Morgan StanleyBoost TargetOverweight$22.00 ➝ $25.00Low
4/6/2022BMO Capital MarketsBoost TargetOutperform$22.00 ➝ $28.00Low
3/11/2022The Goldman Sachs GroupLower TargetBuy ➝ Buy$32.00 ➝ $28.00Low
3/11/2022Raymond JamesLower TargetOutperform$30.00 ➝ $25.00Medium
3/10/2022Morgan StanleyLower TargetOverweight$30.00 ➝ $24.00Medium
3/9/2022CitigroupLower TargetBuy$28.00 ➝ $25.00High
1/18/2022The Goldman Sachs GroupLower TargetBuy$37.00 ➝ $32.00High
11/12/2021Raymond JamesBoost TargetOutperform$25.00 ➝ $30.00High
11/10/2021KeyCorpBoost TargetOverweight$23.00 ➝ $27.00Medium
9/17/2021Raymond JamesBoost TargetOutperform$22.50 ➝ $25.00High
8/16/2021Morgan StanleyBoost TargetOverweight$21.00 ➝ $23.00High
8/16/2021KeyCorpBoost TargetOverweight$21.00 ➝ $23.00High
5/24/2021BMO Capital MarketsInitiated CoverageOutperform$18.00N/A
5/18/2021Raymond JamesInitiated CoverageOutperform$16.50Medium
5/18/2021CitigroupInitiated CoverageBuyMedium
5/18/2021UBS GroupInitiated CoverageNeutral$16.00Medium
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$43.00Medium
5/18/2021BMO Capital MarketsInitiated CoverageOutperform$18.00Medium
5/18/2021Morgan StanleyInitiated CoverageOverweight$21.00Medium
5/18/2021KeyCorpInitiated CoverageOverweight$21.00Medium
5/18/2021Bank of AmericaInitiated CoverageBuy$18.00Medium
5/18/2021Jefferies Financial GroupInitiated CoverageBuy$20.00Medium
(Data available from 3/22/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/23/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2022
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2023
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2023

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Agiliti logo
Agiliti, Inc. engages in manufacturing, management, maintenance, and mobilization of mission-critical, regulated, reusable medical devices. It also offers comprehensive medical equipment management and service solutions to reduce capital and operating expenses, increase medical equipment and staff productivity and support improved patient safety and outcomes. The company was founded in 1939 and is headquartered in Eden Prairie, MN.
Read More

Today's Range

Now: $15.98
Low: $15.45
High: $16.50

50 Day Range

MA: $17.58
Low: $14.52
High: $19.68

52 Week Range

Now: $15.98
Low: $14.15
High: $23.25

Volume

276,278 shs

Average Volume

267,792 shs

Market Capitalization

$2.14 billion

P/E Ratio

76.10

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Agiliti?

The following Wall Street analysts have issued stock ratings on Agiliti in the last year: Bank of America Co., BMO Capital Markets, Citigroup Inc., KeyCorp, Morgan Stanley, Raymond James, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for AGTI.

What is the current price target for Agiliti?

8 Wall Street analysts have set twelve-month price targets for Agiliti in the last year. Their average twelve-month price target is $20.88, suggesting a possible upside of 33.3%. BMO Capital Markets has the highest price target set, predicting AGTI will reach $28.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $18.00 for Agiliti in the next year.
View the latest price targets for AGTI.

What is the current consensus analyst rating for Agiliti?

Agiliti currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGTI will outperform the market and that investors should add to their positions of Agiliti.
View the latest ratings for AGTI.

What other companies compete with Agiliti?

Other companies that are similar to Agiliti include Supernus Pharmaceuticals, SpringWorks Therapeutics, Relay Therapeutics, NuVasive and Immunovant. Learn More about companies similar to Agiliti.

How do I contact Agiliti's investor relations team?

The company's listed phone number is (952) 893-3200 and its investor relations email address is [email protected] The official website for Agiliti is www.agilitihealth.com. Learn More about contacing Agiliti investor relations.